1 Casper Street
Danbury, CT 06810
United States
818 661 5000
https://www.mannkindcorp.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 411
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Michael E. Castagna Pharm.D. | CEO & Director | 1.26M | N/A | 1977 |
Mr. Steven B. Binder | Chief Financial Officer | 800.2k | N/A | 1963 |
Dr. David B. Thomson J.D., Ph.D. | Executive VP, General Counsel & Secretary | 798.53k | N/A | 1967 |
Dr. Stuart A. Tross Ph.D. | Executive VP and Chief People & Workplace Officer | 678.4k | N/A | 1967 |
Mr. Sanjay Singh M.B.A. | Executive Vice President of Technical Operations | 364.53k | N/A | 1966 |
Ms. Lauren M. Sabella | Executive VP & COO | N/A | N/A | 1961 |
Ms. Rosabel Realica Alinaya | VP of Investor Relations & Treasury | 402.26k | N/A | 1961 |
Mr. John F. Bedard | Senior Vice President of Worldwide Regulatory Affairs | N/A | N/A | 1950 |
Mr. James Patrick McCauley Jr., J.D., M.B.A. | Chief Commercial Officer | 614.06k | N/A | 1966 |
Dr. Burkhard Blank M.D. | Executive VP of Research & Development and Chief Medical Officer | N/A | N/A | 1955 |
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corporation’s ISS Governance QualityScore as of March 1, 2024 is 3. The pillar scores are Audit: 6; Board: 3; Shareholder Rights: 4; Compensation: 3.